ArticleFrontiers in pharmacology2026
GUDCA drives colorectal cancer progression via ALKBH5-mediated m6A modification of ENO1 and glycolytic reprogramming.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Colorectal cancer (CRC) is the third most diagnosed malignancy worldwide, yet the mechanisms by which bile acids drive metabolic reprogramming remain unclear. This study investigates whether glycoursodeoxycholic acid (GUDCA) promotes CRC progression through mA epitranscriptomic regulation. Methods: Serum bile acids were profiled in 106 CRC patients and 106 controls by UHPLC-MS/MS. Cellular phenotypes were assessed by CCK-8, colony formation, and xenograft models. mA modification was mapped by meRIP-seq and validated by meRIP-qPCR. Glycolytic function was measured by lactate production, glucose uptake, and ECAR. FXR binding to the ALKBH5 promoter was assessed by luciferase assay and ChIP-qPCR. Clinical correlations were analyzed in 25 CRC patients undergoing Results: GUDCA was the most significantly elevated bile acid in CRC patients and independently predicted poor survival (HR = 3.28, p < 0.001). GUDCA promoted CRC cell proliferation and xenograft tumor growth. Mechanistically, GUDCA antagonized FXR to suppress ALKBH5 transcription, elevating mA modification of ENO1 mRNA and enhancing its translation efficiency. ALKBH5 deficiency drove glycolytic reprogramming and mTORC1 activation. ENO1 silencing abolished GUDCA-induced glycolytic enhancement. Serum GUDCA positively correlated with Conclusion: GUDCA functions as an oncometabolite that drives CRC progression via the GUDCA-FXR-ALKBH5-ENO1 axis, establishing a feed-forward metabolic circuit linking bile acid signaling to mA-mediated glycolytic reprogramming. These findings identify GUDCA and ALKBH5 as potential therapeutic vulnerabilities in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.